Mevidalen
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
2
Sites
123
Countries
4
Endpoints
51
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 51 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 10 of 51 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
3
3
2
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| PRESENCEA Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) | Mevidalen Lewy body dementia | Dementia with Lewy bodies | Ph 2 | Completed | 77 | Jul 2020 | 2 | results |
| NCT06538116A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease | Mevidalen Alzheimer’s disease | Tau biomarker required (plasma) | Ph 2 | Completed | 64 | May 2026 | - |
Showing 1-2 of 2 trials